MRVI Stock Analysis: Buy, Sell, or Hold?
MRVI - Maravai LifeSciences Holdings, Inc. Class A Common Stock
$3.27
-0.10 (-2.97%)
▼
5d:
-13.95%
30d:
-3.82%
90d:
+4.14%
WAIT
LOW Confidence
Last Updated: February 2, 2026
Earnings: Mar 17, 2026
Get Alerted When MRVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MRVI is down 13.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MRVI is down 13.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MRVI is currently trading at $3.27, which is considered slightly low relative to its 30-day fair value range of $3.41 to $3.92.
Technical Outlook: Technically, MRVI is in a strong uptrend. The price is currently testing key support at $3.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.93 (+16.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRVI is in a strong uptrend. The price is currently testing key support at $3.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.93 (+16.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$3.41 -
$3.92
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($3.93)
- WARNING: Recommendation downgraded due to -13.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$3.41 -
$3.92
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.30
Resistance Level
$3.99
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-16.05
Wall Street Target
$3.93
(+16.6%)
Revenue Growth (YoY)
-39.7%
Earnings Growth (YoY)
-32.7%
Profit Margin
-62.9%
Last updated: February 03, 2026 11:51 AM ET
Data refreshes hourly during market hours. Next update: 12:51 PM
Data refreshes hourly during market hours. Next update: 12:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$71 | 60 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$42 | 56 HOLD |
